Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 158

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Preclinical Development of MGC018, a Duocarmycin-based Antibody–drug Conjugate Targeting B7-H3 for Solid Cancer

Scribner, Juniper A., Brown, Jennifer G., Son, Thomas, Chiechi, Michael, Li, Pam, Sharma, Sharad, Li, Hua, De Costa, Anushka, Li, Ying, Chen, Yan, Easton, Ann, Yee-Toy, Nicholas C., Chen, Francine Z., Gorlatov, Sergey, Barat, Bhaswati, Huang, Ling, Wolff, Christina R., Hooley, Jeff, Hotaling, Tim E., Gaynutdinov, Timur, Ciccarone, Valentina, Tamura, James, Koenig, Scott, Moore, Paul A., Bonvini, Ezio, Loo, Deryk · 2020 · Molecular Cancer Therapeutics

Abstract

B7-H3, also referred to as CD276, is a member of the B7 family of immune regulatory proteins. B7-H3 is overexpressed on many solid cancers, including prostate cancer, renal cell carcinoma, melanoma, squamous cell carcinoma of the head and neck, non–small cell lung cancer, and breast cancer. Overexpression of B7-H3 is associated with disease severity, risk of recurrence and reduced survival. In this article, we report the preclinical development of MGC018, an antibody–drug conjugate targeted against B7-H3. MGC018 is comprised of the cleavable linker-duocarmycin payload, valine-citrulline-seco duocarmycin hydroxybenzamide azaindole (vc-seco-DUBA), conjugated to an anti-B7-H3 humanized IgG1/kappa mAb through reduced interchain disulfides, with an average drug-to-antibody ratio of approximately 2.7. MGC018 exhibited cytotoxicity toward B7-H3–positive human tumor cell lines, and exhibited bystander killing of target-negative tumor cells when cocultured with B7-H3–positive tumor cells. MGC018 displayed potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma. In addition, antitumor activity was observed toward patient-derived xenograft models of breast, prostate, and head and neck cancer displaying heterogeneous expression of B7-H3. Importantly, MGC018 exhibited a favorable pharmacokinetic and safety profile in cynomolgus monkeys following repeat-dose administration. The antitumor activity observed preclinically with MGC018, together with the positive safety profile, provides evidence of a potentially favorable therapeutic index and supports the continued development of MGC018 for the treatment of solid cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-20-0116

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 158

Metadata

Authors
Scribner, J. A., Brown, J. G., Son, T., Chiechi, M., Li, P., Sharma, S., Li, H., De Costa, A., Li, Y., Chen, Y., Easton, A., Yee-Toy, N. C., Chen, F. Z., Gorlatov, S., Barat, B., Huang, L., Wolff, C. R., Hooley, J., Hotaling, T. E., Gaynutdinov, T., Ciccarone, V., Tamura, J., Koenig, S., Moore, P. A., Bonvini, E., & Loo, D.
Venue
Molecular Cancer Therapeutics
Published
2020-11-01
Volume
19
Issue
11
Pages
2235-2244
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W3087961054
Cited by
158
References
4
FWCI
9.08
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical Development of MGC018, a Duocarmycin-based Antibody–drug Conjugate Targeting B7-H3 for Solid Cancer. https://app.cochat.ai/papers/10.1158/1535-7163.mct-20-0116
The paper
Scribner, J. A., Brown, J. G., Son, T., Chiechi, M., Li, P., Sharma, S., Li, H., De Costa, A., Li, Y., Chen, Y., Easton, A., Yee-Toy, N. C., Chen, F. Z., Gorlatov, S., Barat, B., Huang, L., Wolff, C. R., Hooley, J., Hotaling, T. E., . . . Loo, D. (2020). Preclinical Development of MGC018, a Duocarmycin-based Antibody–drug Conjugate Targeting B7-H3 for Solid Cancer. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-20-0116

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.